Sinopharm is authorised by the World Health Organization (WHO) for its emergency use listing, and received WHO validation for its safety, efficacy and quality. WHO has thoroughly assessed the data on quality, safety and efficacy of the Sinopharm vaccine and has recommended its use for people aged 18 and above.
The Sinopharm vaccine’s efficacy rate is currently at 79% in preventing symptomatic infection in the multi-country Phase 3 trial. Vaccine efficacy against hospitalization was 79% (95%CI 26–94%). This is compared to 51% for Sinovac’s and 95% for the Pfizer-BioNTech/Cominarty COVID-19 vaccine. More studies are required to prove the BBIBP-CorV’s efficacy against COVID-19 variants.
Sinopharm COVID-19 vaccines works like traditional vaccines, using inactivated virus to trigger our immune system to produce an immune response to fight against the virus. In comparison MRNA vaccines work by injecting the COVID-19 genetic code into the body, triggering the production of viral proteins that trains the immune system to defend against the virus
MOM maintains recommendations
Sinopharm vaccine exposed the body to inactivated COVID-19 virus, to induce the immune system will make antibodies against the coronavirus, attaching to viral proteins. The delivery virus has been attenuated so you won’t develop the common cold when administered with this vaccine. Your body immune system can then respond to an infection of live coronaviruses by producing antibodies to block the virus.
2.Why is it important to get the COVID-19 vaccine?
The Singapore government has advised that COVID-19 vaccination, together with safe distancing measures, contact tracing and proactive testing, will help to protect us and our loved ones against COVID-19. Vaccination will not only reduce the number of people susceptible to the coronavirus, but also reduce the chances of transmission in the community. A high local vaccination coverage is key to protect ourselves from COVID-19, and we encourage all medically eligible persons to be vaccinated.
3. How effective is the Sinopharm vaccine?
The Sinopharm vaccine’s efficacy rate is currently at 79% in preventing symptomatic infection in the multi-country Phase 3 trial. This can be compared to 51% for the Sinovac vaccine and 95% for the Pfizer-BioNTech/Cominarty vaccine. More studies are required to determine COVID-19 vaccine efficacy against COVID-19 variants.
4. Do you need a booster vaccine?
There has been evidence that antibody levels from COVID-19 vaccines, (mRNA vaccines, Sinovac and the Sinopharm BIBP vaccines) decline with time after two doses. A third dose of booster vaccine increases this antibody response substantially. The Expert Committee notes that some individuals have opted for Sinopharm BIBP under the Special Access Route (SAR) as their primary series vaccination and these individuals are also strongly recommended to take a third dose of COVID-19 vaccines for their primary series vaccination. A third dose of the Sinopharm BIBP vaccine is recommended to be given at three months after the second dose to complete their primary vaccination series
5. Who should receive booster vaccination?
The Expert Committee on COVID-19 Vaccination (EC19V) has further recommended that the following persons should receive a booster dose of a COVID-19 vaccine from six months after the completion of the primary
a. Healthcare and frontline workers aged 18 years and above
b. Persons and staff in institutionalised settings aged 18 years and above
c. Persons aged 30 years and above